CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 5-6, 2007, Pages 439-449

  Hasanein, Parisa ^a,b   Parviz, Mohsen ^a   Keshavarz, Mansoor ^a   Javanmardi, Kazem ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BU ALI SINA UNIVERSITY   (Iran)

^c FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amygdala; Cannabinoids; CB1 receptor; Formalin test; Nociception; Rat

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE SEQUENCE; MALE; MICROINJECTION; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN THRESHOLD; RAT; TAIL FLICK TEST; THERMAL STIMULATION;

AMYGDALA; ANALGESICS; ANIMALS; BENZOXAZINES; BORNANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAT; MALE; MICROINJECTIONS; MODELS, ANATOMIC; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PAIN; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TAIL;

EID: 33947635162     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04592.x     Document Type: Article

References (50)

1. Mao J, Price DD, Lu J, Keniston L, Mayer DJ. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett. 2000; 280: 13-16.
2. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol. Ther. 2002; 95: 127-35.
3. de Novellis V, Mariani L, Palazzo E et al. Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. Neuroscience 2005; 134: 269-81.
4. Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res. 1991; 559: 309-14.
5. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 1991; 258: 517-23.
6. Sofia RD, Nalepa SD, Harakal JJ, Vassar HB. Anti-edema and analgesic properties of delta 9-tetrahydrocannabinol (THC). J. Pharmacol. Exp. Ther. 1973; 186: 646-55.
7. Moss DE, Johnson RL. Tonic analgesic effects of delta 9-tetrahydrocannabinol as measured with the formalin test. Eur. J. Pharmacol. 1980; 61: 313-15.
8. Bloom AS, Dewey WL, Harris LS, Brosius KK. 9-nor-9beta- hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: Comparisons with morphine. J. Pharmacol. Exp. Ther. 1977; 200: 263-70.
9. Jacob JJ, Ramabadran K, Campos-Medeiros M. A pharmacological analysis of levonantradol antinociception in mice. J. Clin. Pharmacol. 1981; 21(Suppl.): S327-33.
10. Di Marzo V, Fontana A, Cadas H et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-91.
11. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 1998; 242: 33-6.
12. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: Behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002; 121: 173-90.
13. Yaksh TL, Yeung JC, Rudy TA. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: Observation of differential effects within the periaqueductal gray. Brain Res. 1976; 114: 83-103.
14. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
15. Javanmardi K, Parviz M, Sadr SS, Keshavarz M, Minaii B, Dehpour AR. Involvement of N-methyl-D-aspartate receptors and nitric oxide in the rostral ventromedial medulla in modulating morphine pain-inhibitory signals from the periaqueductal grey matter in rats. Clin. Exp. Pharmacol. Physiol. 2005; 32: 585-9.
16. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 1991; 11: 563-83.
17. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-70.
18. Katona I, Rancz EA, Acsady L et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 2001; 21: 9506-18.
19. McDonald AJ, Mascagni F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: High concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 2001; 107: 641-52.
20. McGaraughty S, Farr DA, Heinricher MM. Lesions of the periaqueductal gray disrupt input to the rostral ventromedial medulla following microinjections of morphine into the medial or basolateral nuclei of the amygdala. Brain Res. 2004; 1009: 223-7.
21. Neugebauer V, Li W, Bird GC, Han JS. The amygdala and persistent pain. Neuroscientist 2004; 10: 221-34.
22. Bernard JF, Besson JM. The spino (trigemino) pontoamygdaloid pathway: Electrophysiological evidence for an involvement in pain processes. J. Neurophysiol. 1990; 63: 473-90.
23. Neugebauer V, Li W. Processing of nociceptive mechanical and thermal information in central amygdala neurons with knee-joint input. J. Neurophysiol. 2002; 87: 103-12.
24. Tershner SA, Helmstetter FJ. Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray. Brain Res. 2000; 865: 17-26.
25. Swanson LW, Petrovich GD. What is the amygdala? Trends Neurosci. 1998; 21: 323-31.
26. Tanimoto S, Nakagawa T, Yamauchi Y, Minami M, Satoh M. Differential contributions of the basolateral and central nuclei of the amygdala in the negative affective component of chemical somatic and visceral pains in rats. Eur. J. Neurosci. 2003; 18: 2343-50.
27. Helmstetter FJ, Bellgowan PS, Tershner SA. Inhibition of the tail flick reflex following microinjection of morphine into the amygdala. Neuroreport 1993; 4: 471-4.
28. Kalivas PW, Gau BA, Nemeroff CB, Prange Jr AJ. Antinociception after microinjection of neurotensin into the central amygdaloid nucleus of the rat. Brain Res. 1982; 243: 279-86.
29. Oliveira MA, Prado WA. Antinociception induced by stimulating amygdaloid nuclei in rats: Changes produced by systemically administered antagonists. Braz. J. Med. Biol. Res. 1998; 31: 681-90.
30. Shin MS. Vasoactive intestinal peptide in the amygdala inhibits tail flick reflexes in rats. Brain Res. 2005; 1040: 197-201.
31. Manning BH, Martin WJ, Meng ID. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience 2003; 120: 1157-70.
32. Manning BH, Merin NM, Meng ID, Amaral DG. Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. J. Neurosci. 2001; 21: 8238-46.
33. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 1999; 822: 237-42.
34. Herkenham M, Lynn AB, Little MD et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 1990; 87: 1932-6.
35. Azami J, Llewelyn MB, Roberts MH. The contribution of nucleus reticularis paragigantocellularis and nucleus raphe magnus to the analgesia produced by systemically administered morphine, investigated with the microinjection technique. Pain 1982; 12: 229-46.
36. Dubuisson D, Dennis SG. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4: 161-74.
37. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA. 1986.
38. Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res. 2003; 987: 176-85.
39. Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R. The formalin test: A validation of the weighted-scores method of behavioural pain rating. Pain 1993; 54: 43-50.
40. Abbott FV, Franklin KB, Westbrook RF. The formalin test: Scoring properties of the first and second phases of the pain response in rats. Pain 1995; 60: 91-102.
41. Manning BH, Franklin KB. Morphine analgesia in the formalin test: Reversal by microinjection of quaternary naloxone into the posterior hypothalamic area or periaqueductal gray. Behav. Brain Res. 1998; 92: 97-102.
42. Naderi N, Shafaghi B, Khodayar MJ, Zarindast MR. Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat. Eur. J. Pharmacol. 2005; 514: 159-64.
43. Palazzo E, Marabese I, de Novellis V et al. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 2001; 40: 319-26.
44. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: Evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 2004; 46: 115-25.
45. Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neurosci. Lett. 2006; 397: 180-4.
46. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 1995; 56: 2103-9.
47. Hajos N, Freund TF. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 2002; 43: 503-10.
48. Manning BH. A lateralized deficit in morphine antinociception after unilateral inactivation of the central amygdala. J. Neurosci. 1998; 18: 9453-70.
49. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol. 1998; 345: 145-53.
50. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 1998; 813: 323-8.